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uterusof articles discussing uterine sarcoma, and this is Part I, which focuses on one of the subtypes of uterine
sarcomasduterine leiomyosarcoma. The clinical characteristics, diagnosis, outcome, and recent advances
are summarized in this article.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Table 1
2014 FIGO and 2010 American Joint Committee on Cancer TNM system for staging
uterine sarcomas (leiomyosarcoma and endometrial stromal sarcoma).
FIGO TNM Deﬁnition
Ia Tumor limited to uterus
IA T1aN0M0 <5 cm
IB T1bN0M0 >5 cm
II Tumor extends beyond the uterus but
limited within the pelvic cavity
IIA T2aN0M0 Adnexal involvement
IIB T2bN0M0 Involvement of other pelvic tissues
III Tumor invades abdominal tissues (not just
protruding into the abdominal cavity)
IIIA T3aN0M0 1 site
IIIB T3bN0M0 >1 site
IIIC T3bN1M0 Pelvic and/or para-aortic lymph node metastases
IV
IVA T4NxM0 Tumor invades bladder and/or rectum
IVB T4NxM1 Distant metastasis
FIGO ¼ Federation International Gynecology and Obstetrics; TNM ¼ tumor, lymph
node, and metastases staging system.
a I is not applied for adenosarcoma (x ¼ 0 or 1).
Table 2
Key factors for evaluation of cytologic atypia.
The following three key factors should be kept in mind:
1. Evaluate atypia at medium power magniﬁcation (10)
2. Compare cytologic features of tumor with surrounding myometrium if
possible
3. Look for background nuclear atypia not atypia of bizarre type that often is
conﬁned to groups of cells in an otherwise banal-appearing leiomyoma
Cytologic atypia includes more than one of the following features:
1. High nuclear size (high nuclear to cytoplasmic ratio)
2. Irregular nuclear membranes
3. Nuclear pleomorphism
4. Hyperchromatism
5. Prominent nucleoli or more than one nucleoliOverview of uterine sarcomas
Uterine sarcomas are rare tumors, accounting for 3e7% of uterine
malignancies and less than 1% of all malignancies from female
genital organs [1e5]. Because of their rarity, unknown etiology, and
highly divergent genetic aberration, there is a lack of consensus on
risk factors for their occurrence and predictive poor outcomes as
well as optimal therapeutic choices. The diversity of uterine sarcoma
can be classiﬁed according to theWorld Health Organization (WHO)
classiﬁcation, which includes the most common uterine leiomyo-
sarcoma (uLMS), endometrial stromal sarcoma (ESS), and undiffer-
entiated uterine sarcoma [3,4]. Based on the WHO classiﬁcation of
soft-tissue sarcomas [4], other rare malignant mesenchymal tu-
mors include adenosarcoma, rhabdomyosarcoma, perivascular
epithelioid cell tumor, malignant type (PEComa), angiosarcoma,
neurogenic sarcoma, osteosarcoma, chondrosarcoma, liposarcoma,
primitive neuroectodermal tumor,myxoﬁbrosarcoma, alveolar soft-
tissue sarcoma, and epithelioid sarcoma.
Carcinosarcomas [malignant mixed mesodermal tumors or
malignant mixed müllerian tumors (MMMTs)] are no longer
considered as sarcoma due to their different spreading pattern.
Carcinosarcomas spread as a dedifferentiated or metaplastic form
of endometrial cancer (EC) [6,7], in which the mesenchymal part
retains epithelial features (i.e., “conversion theory,” which is sup-
ported by variousmolecular studies reporting similar chromosomal
aberrations, cytogenetic aspects, concordant loss of heterozygosity,
identical p53 and K-ras mutations, and matching X-inactivation
patterns in both histological components of the majority of MMMT
cases) [8]. However, because MMMT behaves more aggressively
than the usual type of EC, even for Type II EC [9,10], it is still
included in most retrospective studies of uterine sarcomas, and in
the separate section of “mixed epithelial and mesenchymal tu-
mors” of the 2014 WHO classiﬁcation [4,11]. Besides MMMT, there
are also some arguments for including ESSs because of the signif-
icant difference in their tumor behaviors. ESS is divided into (1) ESS,
low-grade; (2) ESS, high grade; and (3) undifferentiated uterine
sarcoma (UUS) [1,11].
Two staging systems are used for uterine sarcomas, including
the 2014 Federation International Gynecology and Obstetrics
(FIGO) and 2010 American Joint Committee on Cancer tumor,
lymph node, and metastases systems (Table 1). The FIGO staging is
more frequently applied in clinical practice. Tumor grade can be
classiﬁed based on the French Federation of Cancer Centers Sar-
coma Group (FNCLCC) system or the Broder’s system that in-
corporates tumor differentiation, mitotic count, and tumor necrosis
(Grade 1, mild cytologic atypia; Grade 2, more nuclear irregularity;
Grade 3, between Grades 2 and 4; and Grade 4, presence of bizarre
cells) [11]. Evaluation of cytologic atypia is often subjective, but
Oliva et al [11] provided the key components, which can help in
such investigations (Table 2). Because MMMT might be better
classiﬁed as mixed epithelial and mesenchymal tumors, we
excluded the category of MMMT, and only focused on pure uterine
sarcoma, mainly on uLMS and ESS. The series of documents
attempted to provide updated information for this unusual uterine
pathology, and we present by the order of clinical characteristics,
diagnosis, pathology, treatment, and future perspectives.Clinical characteristics and diagnosis
Themedian onset of uterine sarcomas is 50e70 years depending
on the histological subtypes, but most women are of post-
menopausal age. Identiﬁed risk factors, although uncertain, include
previous pelvic irradiation and prior treatment with tamoxifen
[12]. Clinical characteristics of uterine sarcoma vary greatly, and are
also different by the histological subtypes [13]. Most symptoms
and/or signs are nonspeciﬁc, including abdominal pain, enlarged
abdominal circumference, enlarged uterine size, abnormal vaginal
bleeding, and rapid uterine growth in perimenopausal or post-
menopausal women with low estrogen levels. However, one study
argued the relationship between rapid uterine growth and normal
control, because there was no statistically signiﬁcant difference in
the diagnosed sarcoma between rapid uterine growth and normal
control (0.27% vs. 0.23%) [14]. In addition, the absence of speciﬁc
symptoms or signs made the diagnosis of many patients either
incidental (when examining the resected specimen after myo-
mectomy or hysterectomy) or by the appearance of accompanied
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advanced stage [15e18].
Part I: Uterine leiomyosarcoma
Diagnosis
Once tumors are suspected, the two key tools for diagnosis are
radiology and histopathology. Initial assessment of uterine
masses is likely to be clinical and using ultrasound and possibly
magnetic resonance imaging (MRI). Ultrasound, especially
transvaginal ultrasound and colored Doppler ultrasound, is al-
ways considered as the ﬁrst-line assessment because of its cost
effectiveness and reliability [19]. One study showed that higher
sarcoma index, based on three independent risk fac-
torsdincreased neutrophil-to-lymphocyte ratio (>2.1), large tu-
mor size (>8.0 cm), and lower body mass index (body mass index
20)dwas associated with an increased risk of uterine sarcoma
(0, 13.6%; 1, 21.7%; 2, 62.5%; and 3, 100%) [20]. However, because
the study included only a limited number of study population
and had a retrospective nature, its reproducibility is highly
questioned. The Morphological Uterus Sonographic Assessment
group provided the consensus statement about the terms and
deﬁnitions to aim in order to facilitate consistent reporting of
myometrial lesions (a structured report) when using ultraso-
nography in both daily clinical practice and for research purpose
(describing the sonographic appearance of the myometrium and
myometrial lesions and harmonizing nomenclature for future
research) [21]. However, this consensus also found that although
uLMS often presents as purely myometrial lesions and is typically
a single, large tumor, its ultrasound features might not be easily
distinguished from those of ordinary myomas or it may appear as
an irregularly vascularized mass, with a regular or irregular
outline, often with irregular anechoic areas due to necrosis [21],
suggesting that at present, it is not possible to accurately
discriminate between benign and malignant mesenchymal tu-
mors based on any ultrasound parameters [22].
Magnetic resonance imaging
MRI is reported to have a better resolution to distinguish the
components of soft tissues. Therefore, MRI might be an appro-
priate tool for the diagnosis of uLMS. One study from Taiwan
showed that contrast-enhanced MRI (CE-MRI) yielded a signiﬁ-
cantly superior diagnostic accuracy and a signiﬁcantly higher
speciﬁcity than diffusion-weighted MRI (DW-MRI). Besides, CE-
MRI also had a comparably high sensitivity as DW-MRI in the
differentiation between uLMS, smooth muscle tumors of uncer-
tain malignant potential, and uterine ﬁbroids, suggesting that
CE-MRI can provide accurate information and is preferable to
DW-MRI; however, a combination of DW-MRI and apparent
diffusion coefﬁcient value of less than 1.08  103 mm2/s can
achieve a diagnostic accuracy comparable with CE-MRI [23].
Although another early report has agreed on the aforementioned
ﬁndings, they found that apparent diffusion coefﬁcient values for
cellular leiomyomas overlapped [24]. Therefore, Arleo et al [25]
commented that there are no deﬁnitive imaging ﬁndings that
reliably differentiate ordinary leiomyomas from leiomyoma var-
iants (of course, LMS is included), although certain MRI features
indicate the different types of myoma degeneration [25]. Finally,
the use of positron emission tomography/computed tomography
(PET/CT) to differentiate between ordinary leiomyomas, leio-
myoma variants, and LMS remains limited [26,27], because or-
dinary leiomyomas can uptake 18F-ﬂuorodeoxyglucose in PET/CT
[27,28].Hysteroscopy and dilatation and curettage
With regard to uterine carcinoma, hysteroscopy, curettage, and/
or sampling do not always provide useful information about the
disease [4]. Findings in patients with uterine carcinoma may often
be false negative, which results in uncertain diagnosis even when
these patients have abnormal uterine bleeding or postmenopausal
bleeding requiring histological diagnosis [29]. For those symp-
tomatic women, especially after menopause, the polyp, adeno-
myosis, leiomyomas, malignancy, hyperplasiaecoagulopathy,
ovulation dysfunction, endometrial disorders, iatrogenic causes
and not-yet-classiﬁed entities (PALM-COEIN) system should be
applied to minimize the risk of missing diagnosis [29].
Pathology
Among mesenchymal tumors of the uterus, smooth muscle
neoplasms are most common; however, they are a common source
of diagnostic problems, because leiomyoma variants display a wide
spectrum of gross and morphologic appearances often causing a
concern for malignancy [19]. In addition, criteria for diagnosis of
malignant smooth muscle tumors are signiﬁcantly different in soft
tissues from those in the uterus [30]. The main reason is that hor-
monal milieu might inﬂuence the morphology of the uterus. For
example, progestins are associated with increased mitotic activity,
infarction, and other morphologic changes, resulting in the incor-
rect diagnosis [30].
On sectioning of uLMS, a ﬂeshy, variegated cut surface with
common hemorrhage and/or necrosis can be noted. By contrast, if a
smoothmuscle tumor grossly has the typical white, ﬁrm, andwhorl
cut surface, it is often benign [30]. With regard to microscopic
features, uLMS usually displays marked nuclear atypia, highmitotic
rate, and tumor cell necrosis. Mitotic index is an important factor in
establishing the diagnosis of uLMS; however, cutoff values of 10
mitoses/10 high-power ﬁelds, 4 mitoses/10 high-power ﬁelds,
and 2 mitoses/10 high-power ﬁelds are used for spindle, epithe-
lioid, and myxoid uLMS, respectively [11]. Parra-Herran and col-
leagues [31] performed a clinicopathologic analysis of 30 cases of
myxoid uLMS, and concluded that myxoid uLMS is an aggressive
neoplasm characterized by inﬁltrative tumor borders (96%) and
variability of other features [mitotic count (2 mitoses/10 high-
power ﬁelds), atypia (2þ/3þ nuclear atypia means two times the
size and three times the size of the nuclei of adjuvant nonneoplastic
myometrium), and necrosis].
The Broder’s system is one of the frequently used grading sys-
tems applied to uLMS, and it divides uLMS into the following four
categories: Grade 1, mild cytologic atypia; Grade 2, more nuclear
irregularity; Grade 3, between Grades 2 and 4; and Grade 4, pres-
ence of bizarre cells [30]. The FNCLCC system divides soft-tissue
sarcomas into three based on tumor cell necrosis, mitoses, and
degree of differentiation [4].
Evaluation of necrosis of smooth muscle tumors indicated that
three types of necrosis could be encountered: (1) ulceration with
underlying necrosis if submucosal; (2) infarct-type necrosis in
benign and malignant neoplasms; and (3) tumor cell necrosis,
which is speciﬁc for uLMS and deﬁned by an abrupt transition from
necrotic to nonnecrotic areas without interposed granulation tissue
[30]. The infarct-type necrosis should be evaluated in conjunction
with nuclear atypia and mitoses, because of its overlapping
appearance in both benign andmalignant neoplasms [30]. It should
be emphasized that criteria for malignancy are hard to deﬁne with
certainty in epithelioid and myxoid smooth muscle tumors; addi-
tionally, p16, p53, Ki-67, and other cell-cycle regulatory markers are
often not helpful in differentiating between benign and malignant
smooth muscle tumors, as overlap in their expression is common
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outcome have tumors with two or more of the following features:
tumor size of 5 cm or more, inﬁltration, high-grade cytologic fea-
tures, mitotic rate of 1/50 or more high-power ﬁelds, necrosis, or
lymphovascular invasion [30].Treatment
The gold standard of management for uLMS is surgery, and
patients with suspected or conﬁrmed uLMS should have their
uterus removed en bloc, withmaximal effort to avoid intraoperative
rupture, morcellation, or spillage of tumor into the peritoneal cavity
[32]. The indication for adnexa is optional, depending on the pa-
tient’s menopausal status, because the ovaries can be preserved in
young women with tumors limited to the uterus, similar to the
management of early stage EC [9]. Nevertheless, most diagnoses of
uLMS are made a posteriori after surgery for supposed benign
uterine pathology, and procedures resulting in potential tumor
spillage (e.g., morcellation in endobags) might be associated with a
high risk of worsening the prognosis if uLMS is the postoperative
pathological diagnosis [33]. The incidence of retroperitoneal lymph
node metastases is low for uLMS; therefore, it is not recommended
to use pelvic and para-aortic lymph node dissection in routine
practice, even for patients who had been found to have lymph node
involvement, because hematogenous and widespread dissemina-
tion of tumor is usually already present. However, lymphadenec-
tomy can be performed as part of a cytoreductive effort, because
surgical tumor cytoreduction should be attempted in symptomatic
patients with extensive advanced tumors [4]. Cytoreduction should
aim to achievemacroscopically complete resection in one specimen
bloc and minimize microscopically positive margins [33]. This is
best achieved by resecting the tumor en bloc with adherent struc-
tures, even if not overtly inﬁltrated [33], because patients with no
residual disease after surgical resection have an improved survival
rate compared with those who undergo a suboptimal surgical
resection [33]. Pulmonary metastasectomy, preferring wedge
resection, showed a relatively promising result with 5- and 10-year
survival rates of 46.8% and 34.3%, respectively, although the overall
3-year disease-free survival rate was only 27.8% [34], which is very
similar to the management of pulmonary metastases from ECs [35].Adjuvant radiotherapy or systemic therapy for uterine-
conﬁned diseases and completely resected advanced-stage
diseases
Radiotherapy
The role of adjuvant radiation therapy (RT) for patients with
uLMS is highly controversial and it is often not generally indicated
after complete resection of Stage I/II uLMS because the European
Organization for Research and Treatment of Cancer trial 55,874 (a
randomized study, level of evidence II) failed to show any beneﬁt of
postoperative adjuvant RT (50.4 Gy) to treat Stage I and Stage II
uLMS [35]. Postoperative RT did not improve local (20% with RT vs.
24% without RT) or distant progression rates and did not have any
impact on survival [36]. The aforementioned concept is also sup-
ported by results from the Surveillance, Epidemiology, and End
Results database [37]. Among 1088 women with uLMS (22% of
patients with adjuvant RT and 78% without), adjuvant RT had no
effect on survival for Stage I/II (early stage), with a hazard ratio (HR)
of 1.1 and 95% conﬁdence interval (CI) of 0.9e1.4 [37]. However, one
retrospective study from the United States showed the 5-year
locoregional failure-free survival rate to be 87% for 2206 women
with nonmetastatic uterine sarcoma, including uLMS, suggestingthat adjuvant RT is associated with improved outcome compared
with surgery alone (HR ¼ 0.4, p < 0.001) [38].
Recent retrospective studies from Asia showed the relatively
conﬂicted data. One study from China [39] showed that patients
with uLMS undergoing postoperative adjuvant RT might have a
better 5-year locoregional failure-free survival rate and a 5-year
overall survival (OS) rate than those who did not receive post-
operative adjuvant RT (78.7% vs. 44.0%, p ¼ 0.037; 71.8% vs. 40.2%,
p ¼ 0.018, respectively), but another study from South Korea [40]
showed that postoperative adjuvant RT might not reduce pelvic
failure in patients with noncarcinosarcoma type of the uterus
(12.5% vs. 9.9%, p ¼ 0.886). Because of conﬂicted data from the
available studies, the Gynecologic Cancer InterGroup (GCIG)
consensus commented that patients with uLMS after complete
resection of uterus-limited diseases might not have survival ben-
eﬁts when they were managed by adjuvant RT [41].
Chemotherapy
Similar to adjuvant RT, the beneﬁts of CT for patients who had
complete resection for uterus-limited disease are also controversial
[41]. The ﬁrst-line reasonable regimens include doxorubicin (19% of
response rate), doxorubicin plus ifosfamide (17% of response rate
for ifosfamide alone, and 30% of response rate for combination),
gemcitabine (20% of response rate), and gemcitabine plus docetaxel
(36% of response rate), and the second-line therapy includes
pazopanib, trabectedin, dacarbazine, or temozolomide or ﬁxed
dose-rate gemcitabine plus docetaxel after doxorubicin-treated
failure (27% of response rate) [41,42].
Roque and colleagues [43] evaluated 128womenwith uLMS and
the data showed that among 128 women, 56 (44%) with adjuvant
CT, 41 (32%) with adjuvant RT, and 31 (24%) with observation, there
was no difference in progression-free survival (PFS) or OS between
the gemcitabineedocetaxel and other treatment groups, although
the limitations of their study were that 80% of patients belonging to
early stage disease were treated with RT and the mitotic count was
uniformly 10 or greater in the gemcitabineedocetaxel group, sug-
gesting the need for novel therapies to treat uLMS. A multicentric
retrospective study was conducted to evaluate the role of adjuvant
treatment for 140 women with Stage I/II uLMS after surgery [62
patients with observation, 14 patients with RT, 52 patients with CT
(54 patients based on doxorubicin and ifosfamide combination),
and 12 patients with concurrent chemoradiotherapy], and the re-
sults showed that adjuvant CT was not associated with a signiﬁcant
survival beneﬁt (68.7% in the CT þ RT group vs. 65.6% in the
observation group, p ¼ 0.521) [44]. Therefore, the authors
concluded that adjuvant CT should not be considered as a standard
of care for patients with Stage I/II uLMSwithout conﬁrmation of the
randomized clinical studies [44]. By contrast, another multicentric
study that enrolled 108 patients with Stage I/II uLMS (94 in Stage I,
and 14 in Stage II) showed that adjuvant CTmay decrease the risk of
extrapelvic recurrence and improve survival, although the authors
found that women treated with CT had similar recurred rates as
those treated with observation or RT [45]. The other important
ﬁnding in a study by Ricci et al [45] was that after initial CT treat-
ment, recurrences were more likely to be successfully treated or
palliated (p ¼ 0.031).
Omura et al [46] conducted a small prospective randomized trial
to investigate the effect of doxorubicin (60 mg/m2 every 3 weeks in
eight courses) on uterine sarcoma (including uLMS); in their study,
no signiﬁcant advantagewas noted for OS and PFS between the two
groups, although a trend emerged in favor of CT, particular for uLMS
(Table 3) [46]. Hensley et al [42] investigated the efﬁcacy of four
cycles of the combination of gemcitabine and docetaxel in patients
with completely resected uLMS and found that the 2-year PFS rate
Table 3
The response rates of currently popular regimens in the management of patients with uterus-limited leiomyosarcoma or advanced-stage uterine leiomyomas undergoing
complete resection of the tumor.
Regimens Patients (n) Outcome Authors/published y/reference
Doxo vs. Obs 48 RR: 11 (44%) vs. 14 (61%) Omura et al/1985 [46]
Gem þ Doc 15 2-y PFS 59% (median PFS of 39 mo) Hensley et al/2009 [42]
Gem þ Doc followed by Doxo 46 2-y PFS 78% (67e91%)
3-y PFS 57% (44e74%)
Hensley et al/2013 [47]
Doxo þ Ifos þ Cis þ RT vs. RT alone 53 3-y PFS 55% (40e70%) vs. 41% (27e57%)
3-y OS 81% (66e91%) vs. 69% (52e82%)
5-y OS 72% (53e85%) vs. 55% (37e72%)
Pautier et al/2013 [48]
Data are presented as n (%) or 95% conﬁdence interval.
Cis ¼ cisplatin; CR ¼ complete response rate was presented as percentage (n, %); Doc ¼ docetaxel; Doxo ¼ doxorubicin and/or Adriamycin; Gem ¼ gemcitabine;
Ifos ¼ ifosfamide; Obs ¼ observation; OS ¼ overall survival; PFS ¼ progression-free survival; PR ¼ partial response rate was presented as percentage (n, %); RR ¼ recurrence
rate; RT ¼ radiotherapy.
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months (Table 3). A 3-year Phase II trial (SARC 005) evaluated 46
patients with uLMS who received treatment with four cycles of
gemcitabine (900 mg/m2 on Day 1 and Day 8) plus docetaxel
(75 mg/m2 on Day 8 with a 21-day interval) followed by doxoru-
bicin. Their data showed that the median time to recurrence was
27.4 months, and the 2-year PFS and 3-year PFS were 78% and 57%,
respectively (Table 3), suggesting the need for a prospective ran-
domized trial of adjuvant CT versus observation to determine
whether adjuvant CT can improve survival in women with uterus-
limited uLMS [47].
A French randomized study enrolling 53 patients with uLMS
showed that the combination of four cycles of multiagent CT
therapy (a 28-day interval), including doxorubicin, ifosfamide,
cisplatin, and RT (45 Gy in 5 weeks), might provide a better 3- or 5-
year disease-free survival than RT alone (51% vs. 40% or 51% vs. 29%;
Table 3) [48]. In fact, the primary end point of this French study was
met with the improvement in the 3-year PFS [48]. Although these
results of adjuvant CT seemed to be promising, the multiagent CT
and the combination of CT and RT were associated with statistically
signiﬁcantly increased toxicity, including two deaths in a French
randomized study, and therefore the GCIG consensus did not
recommend adjuvant CT as a standard treatment for uterus-limited
uLMS patients [41]. Furthermore, the key components against the
routine use of adjuvant CT are the heterogeneity of the tumor types
and their stages and the very small sample size and no OS beneﬁt
[41]. However, the GCIG consensus agreed that for patients with
locally advanced completely resected uLMS, postoperative sur-
veillance and/or therapy could be individualized.Adjuvant radiotherapy or systemic therapy for advanced diseases
and recurrent diseases
The value of adjuvant CT might be important for advanced or
recurrent uLMS [49]. By contrast, RT might only play a minor role in
such cases. At present, doxorubicin-based CT, especially doxoru-
bicin as a single agent, remains the best choice as a ﬁrst-line
treatment for uLMS that is not amenable to curative-intent sur-
gery [50], because the results of gemcitabine-based chemotherapy
are conﬂicting (5% of complete response rate and 20e30% of partial
response rate) [49]. A summary of current therapeutic agents in
uLMS treatment showed that the response rates of these studies
seemed to be relatively disappointing with complete response rate
less than 10% (4.8% and 6.3%, respectively) [51,52] and partial
response rate in less than one third of patients [51e63] (Table 4).
For single-agent liposomal doxorubicin regimen, patients
received liposomal doxorubicin (50 mg/m2) intravenously over 1
hour and courses were repeated every 4 weeks [55]. For single-
agent paclitaxel regimen, patients received paclitaxel (175 mg/m2) intravenously over 3 hoursd135 mg/m2 paclitaxel for patients
with prior pelvic RTdand courses were repeated every 3 weeks
[56,57], but the dose of paclitaxel can be reduced by 110 mg/m2
[57]. For single-agent gemcitabine regimen, intravenous gemcita-
bine was administered over 30 minutes at a dose of 1000 mg/m2 on
Days 1, 8, and 15, with cycles repeated every 28 days [58]. For
single-agent ifosfamide regimen, patients received ifosfamide
(1.5 g/m2) daily intravenously for 5 days with mesna (2-
mercaptoethane sodium sulfonate), and the dosage of ifosfamide
could be reduced to 1.2 g/m2 for those who had received prior RT
[59]. For single-agent etoposide regimen, patients received an oral
form of 50 mg/m2/d (30e40 mg/m2/d for those with prior RT) as a
single dose for 21 days, every 28 days [60]. Trabectedin (1.5 mg/m2)
was administered intravenously over 24 hours every 3 weeks [63].
The combination of gemcitabine and docetaxel was prescribed
as follows: gemcitabine (675e900 mg/m2) on Days 1 and 8 over 90
minutes, gemcitabinewith docetaxel (60e100mg/m2) on Day 8 of a
21-day cycle with granulocyte growth factor, based on previous RT
status [51,53]. For adding bevacizumab in the combination of
gemcitabine and docetaxel, bevacizumab (15 mg/kg) was intrave-
nously administered over 90 minutes after gemcitabine adminis-
tration on Day 1 [53]. The combination of ifosfamide and
doxorubicin involved administration of ifosfamide (5.0 g/m2/24 h)
and mesna (6.0 g/m2/36 h) by continuous intravenous infusion
preceded by intravenous administration of doxorubicin (50mg/m2)
over 15 minutes of a 21-day cycle if counts allowed [54]. For a
combination regimen of mitomycin, doxorubicin, and cisplatin,
patients received mitomycin (8 mg/m2) and doxorubicin (40 mg/
m2) intravenously, followed immediately by cisplatin (60mg/m2) in
1 L of 0.45% saline plus mannitol (25 g) [61]. For combination
regimen of dacarbazine, mitomycin, doxorubicin, and cisplatin
regimen, the patients were treated with sargramostim 250 mg/m2
subcutaneously over 12 hours for 4 days (days 6 through 3),
followed by a 2-day rest (days 2 and 1) [62]. Then, chemo-
therapy on day 0 consisting of dacarbazine of 750 mg/m2 intrave-
nously over 2 hours, mitomycin 6 mg/m2 intravenously,
doxorubicin 40 mg/m2 intravenously and cisplatin 60 mg/m2
intravenously over 2 hours was prescribed [62]. Finally,
sargramostim 250 mg/m2 was administered subcutaneously at
12-hour interval on days 1 through 14 [62]. Patients were retreated
at 4-week intervals [62]. Administration of the combination of
doxorubicin and trabectedinwas as follows: 60 mg/m2 doxorubicin
by a 10e15-minute central venous infusion on Day 1, followed by a
3-hour central venous infusion of 1.1 mg/m2 trabectedin on Day 1,
then a subcutaneous administration of pegﬁlgrastim (6 mg) on Day
2. The treatment was given every 3 weeks for a maximum of six
cycles [64]. The regimens and dosages are summarized in Table 5.
Gupta et al [65] proposed a clinical practice guideline, and
suggested that doxorubicin has been considered the standard of
Table 4
Summary of trials to investigating the role of adjuvant therapy for patients with advanced and recurrent uterine leiomyosarcomas.
Regimens/trials Patients (n) Outcome Authors/published y
Gem þ Doc/Phase 2/ﬁrst line 42 PFS 4.4 mo (15, 35.5%) Hensley et al/2008 [51]
Gem þ Doc/Phase 2/second line 51 PFS 6.7 mo (13, 27%) Hensley et al/2008 [52]
Gem þ Doc vs. Gem þ Doc þ bevacizumab/Phase 3/ﬁrst line 54 vs. 53 PFS 6.2 mo vs. 4.2 mo (17, 31.5%)
OS 26.9 mo vs. 23.3 mo (19, 35.8%)
Hensley et al/2015 [53]
Ifos þ Doxo/Phase 2/ﬁrst line 33 (10, 30%) Sutton et al/1996 [54]
Liposomal Doxo/Phase 2/ﬁrst line 35 (5, 14.3%) Sutton et al/2005 [55]
Paclitaxel/Phase 2/ﬁrst line 34 (3, 9.1%) Sutton et al/1999 [56]
Paclitaxel/Phase 2/second line 53 (4, 8.4) Gallup et al/2003 [57]
Gem/Phase 2/second line 48 (9, 20.5%) Look et al/2004 [58]
Ifos/Phase 2/ﬁrst line 35 (6, 17.2%) Sutton et al/1992 [59]
Oral etoposide/Phase 2/ﬁrstesecond line 36 (2, 6.95) Rose et al/1998 [60]
Mitomycin þ Doxo þ Cis/Phase 2/ﬁrst line 41 (8, 23%) Edmonson et al/2002 [61]
Dacarbazine þmitomycin þ Doxo þ Cis/Phase 2/ﬁrst line 18 (5, 27.8%) Long et al/2005 [62]
Trabectedin/Phase 2/ﬁrst line 20 (2, 10%) Monk et al/2012 [63]
Trabectedin þ Doxo/Phase 2/ﬁrst line 47 (47, 87.2%) Pautier et al/2015 [64]
Trabectedin vs. dacarbazine/Phase 3/second line 134 vs. 78 PFS 4.0 mo vs. 1.5 mo Demetri et al/2016 [67]
Data are presented as n (%) or 95% conﬁdence interval.
Cis ¼ cisplatin; CR ¼ complete response rate was presented as percentage (n, %); Doc ¼ docetaxel; Doxo ¼ doxorubicin and/or Adriamycin; Gem ¼ gemcitabine;
Ifos ¼ ifosfamide; Obs ¼ observation; OS ¼ overall survival; PFS ¼ progression-free survival; PR ¼ partial response rate was presented as percentage (n, %); RR ¼ recurrence
rate; RT ¼ radiotherapy.
Table 5
Current use of chemotherapy regimen.
Regimen Dosage Interval
Trabectedin Trabectedin >24 h (1.5 mg/m2, Day 1) A 21-d interval
Doxorubicin Doxorubicin 60 min (50e75 mg/m2, Day 1) A 21-d interval
Liposomal doxorubicin Liposomal doxorubicin 60 min (50 mg/m2, Day 1) A 28-d interval
Ifosfamide Ifosfamide 24 h (1.2e1.5 g/m2, Day 1eDay 5) with mesna A 28-d interval
Paclitaxel Paclitaxel >3 h (175 mg/m2 or 110e135 mg/m2, Day 1) A 21-d interval
Etoposide Oral etoposide (50 mg/m2, Day 1eDay 21) A 28-d interval
Doxorubicin and trabectedin Doxorubicin 15 min (60 mg/m2, Day 1)
Trabectedin >24 h (1.1 mg/m2, Day 1)
A 21-d interval
Ifosfamide and doxorubicin Doxorubicin 15 min (50 mg/m2, Day 1)
Ifosfamide 24 h (5.0 gm/m2, Day 1 and mesna, 6.0 g/m2/36 h)
A 21-d interval
Gemcitabine and docetaxel Gemcitabine 90 min (675e900 mg/m2, Day 1eDay 8)
Docetaxel 60 min (60e100 mg/m2, Day 8)
A 21-d interval
Doxorubicin, ifosfamide, and cisplatin Doxorubicin 60 min (50 mg/m2, Day 1)
Ifosfamide 24 h (3 g/m2, Day 1eDay 2)
Cisplatin >2 h (75 mg/m2, Day 3)
A 28-d interval
Mitomycin, doxorubicin, and cisplatin Mitomycin 30 min (8 mg/m2, Day 1)
Doxorubicin 30 min (40 mg/m2, Day 1)
Cisplatin >2 h (60 mg/m2, Day 1)
A 28-d interval
Dacarbazine, mitomycin, doxorubicin, and cisplatin Dacarbazine >2 h (750 mg/m2, Day 1)
Mitomycin 30 min (6 mg/m2, Day 1)
Doxorubicin 30 min (40 mg/m2, Day 1)
Cisplatin >2 h (60 mg/m2, Day 1)
A 28-d interval
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dence supported the alternative choices of the other agent (gem-
citabine), whichmight be valuable in the future clinical trials [50]. A
recent ongoing trial (a prospective randomized controlled Phase III
trial of gemcitabine and docetaxel compared with doxorubicin as
ﬁrst-line treatment in previously untreated advanced unresectable
or metastatic soft-tissue sarcomas), although not yet fully pub-
lished, showed a similar outcome between doxorubicin (75 mg/m2
every 3 weeks) and gemcitabine (650 mg/m2 on Days 1 and 8 every
3 weeks) and docetaxel (75 mg/m2 every 3 weeks), but the toler-
ance of doxorubicin appeared better [50].
Trabectedin (YONDELIS) is a tetrahydroisoquinoline alkaloid,
originally isolated from the marine tunicate Ecteinascidia turbinata
and works based on interaction with the minor groove of the DNA
double helix, which triggers a cascade of events that interfere with
several transcription factors, DNA binding proteins, and DNA repair
pathways, resulting in G2eM cell-cycle arrest and ultimately
apoptosis [66]. Monk et al [63] reported the results from a Phase II
study (Gynecologic Oncology Group: GOG 87M) and conﬁrmed themodest activity of trabectedin as the ﬁrst-line therapy in advanced,
persistent, or recurrent uLMS [63]. In addition, no unusual toxicities
were found, and more than half of the patients had more than 6
months of PFS and did not have treatment-ending toxicity for more
than 10 cycles [63], suggesting that PFS rather than overall response
rate would have been a better metric to assess the activity of this
drug in uLMS patients [63,66].
The value of trabectedin, especially combined with other anti-
neoplastic agents as ﬁrst-line therapy, seemed to be further sup-
ported by a Phase II nonrandomized, multicenter trial (LMS-02) by
the French Sarcoma Group [64]. Among a total of 47 patients with
uLMS who were treated with trabectedin and doxorubicin, 28
women (59.6%, 95% CI 44.3e73.6) achieved a partial response and
13 women (27.7%, 95% CI 15.6e42.6) had stable disease; 41 women
(87.2%, 95% CI 74.3e95.2) achieved disease control [64]. The data of
the LMS-02 study support the notion that the combination of
doxorubicin and trabectedin is an active ﬁrst-line regimen for
advanced uLMS that provides clinically meaningful beneﬁts to pa-
tients with uLMS, and the therapeutic beneﬁts possibly result from
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also showed that the rate of progression seems to increase after 6
months, which raises the question of whether treatment should be
continued with trabectedin alone [64]. A Phase III randomized
multicenter clinical trial was conducted to compare the effects of
trabectedin with dacarbazine in patients with advanced lip-
osarcoma or LMS after prior therapy with an anthracycline and at
least one additional systemic regimen; in this study, 212 patients
were uLMS cases [67]. Among the patients with uLMS, 134 patients
received trabectedin treatment and 78 received dacarbazine ther-
apy. The results showed HR of 0.58 (95% CI 0.41e0.81) for PFS in the
trabectedin group compared with the dacarbazine group, which
signiﬁcantly favored the survival beneﬁts of trabectedin treatment
[67]. Of most importance, there are two advantages of using the
trabectedin treatment: (1) the therapeutic beneﬁt of continued
disease control can be maintained by extended trabectedin dosing
beyond six cycles, which has been reported in a recent study as well
[68]; (2) the safety and tolerability of trabectedin were consistent
with extensive prior experience and reports [69]. All these ﬁndings
suggested that trabectedin might be a promising drug in the
management of this highly lethal diseaseduLMS.
Finally, some investigating tools, including cytoreductive surgery
with hyperthermic intraperitoneal CT (CRS-HIPEC), have been re-
portedas the treatmentmost likely to achieveprolonged survival for
peritoneal surface disease fromvarious primaries [70]. For uLMS, the
role of CRS-HIPEC needsmuch evidence to conﬁrm its effectiveness.Future perspectives
Recently, somatic variation in LMS using exome sequencing
strategy revealed that tumor protein P53, alpha thalassemia/
mental retardation syndrome X-linked (ATRX) gene, and mediator
complex subunit 12 are frequently mutated in LMS, and alternative
lengthening of telomeres phenotype was commonly seen in LMS.
These ﬁndings indicated that ATR inhibitors might be a new
possible drug for ATRX-deﬁcient tumor, providing a potential novel
therapeutic option for LMS [71,72]. However, the beneﬁts of target
therapy for uLMS are unclear. For example, a randomized Phase III
trial was conducted to determine whether the addition of bev-
acizumab to gemcitabineedocetaxel increases PFS in uLMS [53].
The results showed that median PFS was 6.2 months for gemcita-
bineedocetaxel plus placebo versus 4.2 months forFigure 1. A ﬂowchart for the clinical practice in the management of women with a
diagnosed uterine leiomyosarcoma. BSO ¼ bilateral salpingo-oophorectomy;
CT ¼ chemotherapy; FIGO ¼ Federation International Gynecology and Obstetrics;
RT ¼ radiation therapy; TAH ¼ total hysterectomy; U-LMS ¼ uterine leiomyosarcoma.gemcitabineedocetaxel plus bevacizumab (HR ¼ 1.12; p ¼ 0.58); in
addition, median OS was 26.9 months for gemcitabineedocetaxel
plus placebo and 23.3 months for gemcitabineedocetaxel plus
bevacizumab (HR ¼ 1.07; p ¼ 0.81). Both seemed to be similar. In
fact, the authors found that a Phase II single-agent study of
vascular-targeted agents has mostly yielded negative results;
therefore, it is not surprising that antivascular-directed therapy
might not play any role in the management of uLMS. The multi-
kinase inhibitorsdsunitinib and sorafenibdfailed to meet the
study’s criteria for further investigation of these agents in uLMS
[73,74]. Although pazopanib showed the longer median PFS
compared with placebo (4.6 months, 95% CI 3.7e4.8 months vs. 1.6
months, 95% CI 0.9e1.8 months) with an HR of 0.31 (95% CI
0.24e0.40; p < 0.0001), OS seemed not to reach a statistically sig-
niﬁcant difference between the two groups (12.5 months, 95% CI
10.6e14.8 months in the pazopanib group vs. 10.7 months, 95% CI
8.7e12.8 months in the placebo), with an HR of 0.86 (95% CI
0.67e1.11; p ¼ 0.25) [75].
Conclusion
The standard treatment for early and far-advanced uLMS is hys-
terectomy plus bilateral salpingo-oophorectomy and complete
cytoreduction of the tumor en blocwith adherent structures, even if
not overtly inﬁltrated, respectively. For early stage (uterus-limited)
disease, themost important thing is that tumor should be removed in
intact and en bloc status, although minimally invasive surgery is
applied [76,77]. For far-advanced disease, the results of the Taiwan
Gynecology Oncology Group 2005 (TGOG-2005) showed that
adequate debulking surgery, including dissection of both pelvic and
para-aortic lymphnodes,might provide a better chance of survival in
FIGO IIIeIV pure endometrioid-type EC cases [78], which might be
also feasible. In fact, residual diseasehas anegativeprognostic impact
[79], and metastasectomy should be considered for patients with
metastatic uLMS. Adjuvant RTand CTare not administered in routine
practice because the survival beneﬁts are doubtful, especially for
patientswith totallyeradicated tumors. Treatmentoutcomes inuLMS
are disappointing, especially in patients with inoperable, locally
advanced, recurrent and/or metastatic diseases. Figure 1 presents
some useful treatment options when dealing with uLMS patients.
Available evidence of chemotherapy for uLMS is shown below. Tra-
bectedin might be one of very promising agents. Other effective
regimens include single agent of doxorubicin and gemcitabine, and
the combination of therapy, such as gemcitabine plus docetaxel and/
or trabectedin-based combination therapy. Besides the waiting for
information provided by randomized clinical trials, addition efforts
could focus on better deﬁning the molecular etiology of uLMS to
provide better care for this highly lethal disease.
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